Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Leishen Energy Holding Co., Ltd. - Ordinary Shares (NQ:LSE)

12.50 +4.73 (+60.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,045,153
Open 11.44
Bid (Size) 11.15 (10)
Ask (Size) 11.45 (1)
Prev. Close 7.770
Today's Range 11.13 - 14.99
52wk Range 3.760 - 14.99
Shares Outstanding 75,936,172
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
From HUTCHMED (China) Limited
Via GlobeNewswire
Stay updated with the stocks that are on the move in today's after-hours session.
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill

Performance

YTD
+141.8%
+141.8%
1 Month
+127.3%
+127.3%
3 Month
+187.4%
+187.4%
6 Month
+187.4%
+187.4%
1 Year
+187.4%
+187.4%

More News

Read More
Nasdaq Gains Over 1%; Williams-Sonoma Shares Plunge After Q4 Results
Via Benzinga
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
From HUTCHMED (China) Limited
Via GlobeNewswire
Why StoneCo Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Nexxen Expands U.S. Partnership with Tubi to U.K.
From Nexxen International Ltd.
Via GlobeNewswire
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Executive Appointments Strengthen Nexxen’s Data, Streaming and Omnichannel Expertise
From Nexxen International Ltd.
Via GlobeNewswire
Caledonia Mining Corporation Plc: Notice of Results and Investor Presentation
From Caledonia Mining Corporation Plc
Via GlobeNewswire
Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference
From AVACTA GROUP PLC
Via GlobeNewswire
Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts
From AVACTA GROUP PLC
Via GlobeNewswire
HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED to Announce 2024 Final Results
From HUTCHMED (China) Limited
Via GlobeNewswire
Caledonia Mining Corporation Plc: Appointment of New Chief Financial Officer
From Caledonia Mining Corporation Plc
Via GlobeNewswire
Leishen Energy Holding Co., Ltd. Announces Fiscal Year 2024 Financial Results Highlighting Strong Operating Cash Flow and Stable Gross Margins
From Leishen Energy Holding Co., Ltd.
Via GlobeNewswire
Caledonia Mining Corporation Plc: Appointments of Stefan Buys and Lesley Goldwasser as Non-Executive Directors
From Caledonia Mining Corporation Plc
Via GlobeNewswire
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Metals & Mining Virtual Investor Conference Agenda Announced for February 12th and 13th
From Virtual Investor Conferences
Via GlobeNewswire
Nexxen Fuels Growth with Live Sports Offerings and Key Partnerships, Reaching Highly Engaged Audiences Across Channels
From Nexxen International Ltd.
Via GlobeNewswire
Caledonia Mining Corporation Plc: Blanket Mine Q4 and FY 2024 Production and 2025 Guidance
From Caledonia Mining Corporation Plc
Via GlobeNewswire
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
From HUTCHMED (China) Limited
Via GlobeNewswire
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Nexxen Launches Nexxen U, a First-of-its-Kind Education Program for Linear, Connected TV and Digital Convergence
From Nexxen International Ltd.
Via GlobeNewswire
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
From HUTCHMED (China) Limited
Via GlobeNewswire

Frequently Asked Questions

Is Leishen Energy Holding Co., Ltd. - Ordinary Shares publicly traded?
Yes, Leishen Energy Holding Co., Ltd. - Ordinary Shares is publicly traded.
What exchange does Leishen Energy Holding Co., Ltd. - Ordinary Shares trade on?
Leishen Energy Holding Co., Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Leishen Energy Holding Co., Ltd. - Ordinary Shares?
The ticker symbol for Leishen Energy Holding Co., Ltd. - Ordinary Shares is LSE on the Nasdaq Stock Market
What is the current price of Leishen Energy Holding Co., Ltd. - Ordinary Shares?
The current price of Leishen Energy Holding Co., Ltd. - Ordinary Shares is 12.50
When was Leishen Energy Holding Co., Ltd. - Ordinary Shares last traded?
The last trade of Leishen Energy Holding Co., Ltd. - Ordinary Shares was at 03/19/25 04:00 PM ET
What is the market capitalization of Leishen Energy Holding Co., Ltd. - Ordinary Shares?
The market capitalization of Leishen Energy Holding Co., Ltd. - Ordinary Shares is 949.20M
How many shares of Leishen Energy Holding Co., Ltd. - Ordinary Shares are outstanding?
Leishen Energy Holding Co., Ltd. - Ordinary Shares has 949M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.